Michelle Fitts, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,070 of the $1,254 with a category attached, or 85.3%. 18 manufacturers reported payments, led by Astellas Pharma US Inc at 32.1% of the total.
Across 50 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$402
- Bayer$162
- Boston Scientific$84
- Dendreon Pharmaceuticals LLC$83
- Myriad Genetic Laboratories, Inc.$65
- AbbVie$62
- plus $396 from 12 others
What the payments were for
- Food & beverage$1,07085%
- Education$18415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 17 | $402 |
| Bayer | 3 | $162 |
| Boston Scientific | 3 | $84 |
| Dendreon Pharmaceuticals LLC | 3 | $83 |
| Myriad Genetic Laboratories, Inc. | 3 | $65 |
| AbbVie | 3 | $62 |
| Coloplast | 3 | $55 |
| 180 Medical, Inc. | 2 | $55 |
| Axonics, Inc. | 1 | $52 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Tolmar, Inc. | 2 | $38 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Merck | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$116
How this compares
$1,254 in reported general payments places this provider in the 80th percentile of 229 surgical providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $13,503 |
| GemtesaVibegron | 17 | $10,318 |
| Tamsulosin Hcl | 226 | $4,166 |
| Testosterone | 11 | $1,786 |
| Estradiol | 33 | $1,599 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,453 |
| Testosterone Cypionate | 20 | $1,441 |
| Trospium Chloride | 19 | $1,363 |
| Finasteride | 71 | $1,340 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 22 | $625 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $525 |
| Silodosin | 17 | $433 |
| Cephalexin | 54 | $192 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $152 |
| Oxybutynin Chloride | 47 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $402 | $13,50316 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $10,31817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 229 surgical providers in Oregon.
Other surgical in Bend
- Richard OmbrembowskiBend$3K
- Lindsey ReeseBend$3K
- Jason WinebargerBend$3K
- Lauren BeebeBend$2K
- Daniel WeilandBend$1K
- Amy HowardBend$1K
- Benjamin WalshBend$1K
- Jonathan MunnsBend$1K
- Alyssa ArgabrightBend$1K
- James BerkingMedford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.